Thread: DepoMed Inc. - DEPO

StockPreacher.com Issues Trading Outlook for DepoMed Inc. GlobeNewswire ***"GlobeNewswire "
DALLAS , Oct. 7, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring DepoMed Inc. (NasdaqEPO). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on DepoMed Inc. (NasdaqEPO) should be of particular interest to comparable companies: MannKind Corp. (Nasdaq:MNKD), Novo Nordisk A/S (NYSE:NVO), Elan Corp. (NYSE:ELN) and Biovail Corp. (NYSE:BVF).

The full report is available at: .:StockPreacher:.

Get our alerts BEFORE the rest of the market. Follow us on Twitter: Stock Preacher (StockPreacher) on Twitter

DepoMed Inc. (DEPO) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. DEPO has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. ( Santarus ); and ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that DEPO commercializes in the United States with Watson Pharma (Watson).

Message Board Search for DEPO: BoardCentral: Messages for DEPO (DepoMed Inc.)

In the report, the analyst notes:

"DEPO recently announced top-line results from a phase III clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA . The primary endpoint measured pain scores from baseline to the end of a 10-week treatment period using the numerical Likert pain scale. DM-1796 is an investigational extended release, once-daily tablet formulation of gabapentin for the treatment of PHN. DEPO has licensed DM-1796 to Solvay Pharmaceuticals Inc. in the United States , Canada and Mexico for the treatment of pain.

"In July, the Company announced that it provided a license to certain patents directed to metformin extended release technology to Merck & Co. Inc. to be used in developing fixed dose combinations of sitagliptin and extended release metformin. Under terms of the agreement, Merck will receive a non-exclusive license, as well as other rights to certain DEPO patents directed to metformin extended release technology. In exchange DEPO will receive a $10 million upfront fee."

To read the entire report visit: .:StockPreacher:.

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: Penny Stocks, Small-cap Stock Tips, Trading and Picks, Penny Stock Investment Newsletter

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC . Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT: StockPreacher.com Jeff Bishop (469)-252-3505 press@beaconequity.com

DEPO DepoMed Inc The drugmaker of a long-acting treatment for hot flashes said the drug failed to meet three of four goals in two separate studies. 3.97 -2.39 / -37.58%